Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seriously Now, we got fast track designation, can we AT LEAST keep the price above $3something and NOT go back down to $2.50 like we always do.
What more do investors want?
Where did you get this info from?
Is it real actual info, or just a hope/wish/guess?
Thanks, I was heading to bed at 11PM when I read your post. It's now way past 4AM.
Some of what I gathered so far:
TTI-621 blocks the CD47 "Do Not Eat" signal, and then the bodies own immune system is supposed to "eat" the cancer. Further, the IgG1 Fc function adds an additional "eat" signal.
In the chart "Highlights of TTI-621 Parts 1-3 data" their Objective response rates of 19%, 18%, 29%, 24%.
"Objective response rates includes partial response and complete response rates"
Complete response rates of 1(2%), 2(9%), 1(14%), 1(4%) leave Partial response rates of 17%, 9%, 15%, 20%. All in Phase 1.
TTI-622, also in Phase 1, basically the same function except IgG4 Fc instead of an IgG1 Fc. IgG4 Fc gives less of an "eat" signal, but has better tolerance, so TTI-622 can potentially be given in higher doses, and also in combination with other agents.
Other interesting info:
April 30, 2019. Niclas Stiernholm resigned as CEO after 17 years (long time).
September 25, 2019. Trillium Therapeutics Appoints Jan Skvarka as CEO.
In connection with the appointment of Mr. Skvarka as Chief Executive Officer, the Board of Directors has granted to Mr. Skvarka an option to purchase 1,800,000 common shares under the 2019 Inducement Plan at an exercise price equal to the closing market price of Trillium’s common shares on September 24, 2019 (which closed at 39 cents), so not a bad deal, that's up 7.2 million so far.
A bunch more technical info, but I'm not a scientist. They do have some Complete responses early on. I'm not so sure about the ... then the bodies own immune system is supposed to "eat" the cancer part. It seems to leave it up to the sick body to heal itself without any … what I'll call … outside administered help like MultiTAA does, which also has the additional positive benefit of epitope spreading.
TRIL is also up from $1.20 to $4.20 in the last 2 weeks. Less then 3% shorts (so far).
28% held by institutions. Matrix, NEA, Morgan Stanley, + Baker Brothers being the largest investors.
They just had a 102 million dollar offering priced at $2.75.
TG Therapeutics TGTX and several other larger players also working on CD47.
I don't know, my head hurts from reading, I'm going to bed, good luck with it if you load up.
I don't understand … with all this potential … WHY we can't AT LEAST hold above $3.
Are we going back BELOW 2.50 now, as usual?
Hi, I don't think there is anyone more pissed off on this board than me over MRKR's current price and situation as MRKR is 70% of my non real estate investments.
Concerning ASCO, I initially felt the same way and stated it, but Phantom and others pointed out that the ASCO screw up had nothing with MRKR, it was the responsibility of the folks at Baylor who screwed up (STILL SUCKED THOUGH).
As far as the reagents and MRKR not having the Certificate of Analysis for those two reagents (WHICH STILL SUCKS), I just don't know. I'm sure Phantom or others can find out what the facts are.
I'm kind of pissed that James Allison hasn't contacted high profile pancreatic cancer patients like Alex Trebek and saying something like:
"Hi, I'm James Allison, I just won the Nobel Prize for medicine, perhaps you should consider MRKR's technology".
He has the credentials to actually get through and make contact, but again, I don't know, he may have done that.
I sent an email to his agent, but I'm sure an email from a nobody didn't carry much weight.
I'm also pissed with jerks like Citadel and Susquehanna hedge funds shorting MRKR to death, and over the fact that the SEC changed the uptick rule for short selling.
I see so many biotech's with nothing pipelines compared to MRKR being given valuations that are 5 times or 10 times MRKR's it's just ridiculous.
Having said all of that, I still think/believe/hope that it is just a matter of time for us MRKR shareholder and needy patients (I HOPE).
But I know that the continued waiting also STILL SUCKS.
OK, step one, stay above $3.
step two, get some good news.
step three, chase short sellers away.
step four, get to fair valuation we deserve.
AVXL got up to $3.23 today. How long before it is BELOW $2.50 AGAIN?
I'm opposite, it would shock me if MRKR did not PR any FDA trial lift.
I know MRKR isn't a PR animal, but Most biotechs would PR a lift, it's probably would show up in Benzinga or somewhere anyway.
it would be GREAT if NEXT WEEK AVXL, Anavex Life Sciences GETs ABOVE $3 AND STAYs THERE AND CLIMBs HIGHER.
that would be a nice start to 2020 after all the problems/issues/hassles with AVXL last year and recently.
NEXT WEEK WE NEED MRKR, Marker Therapeutics, TO GET ABOVE $3 AND STAY THERE AND CLIMB HIGHER.
that would be a nice needed XL (extra-large) bonus.
DOES XL HAVE ISSUES?
Should start to rise dramatically once revenues start to roll in during 2020. Accumulate now while it's crazy cheap hammered down.
Buy ATNM now that's it's cheap before it pops in 2020.
Buy next week like Mad - so that in March you won't be Sad.
Thanks, a comment and a question. I get what you're saying about no great pressure or incentive to buy, but what I don't get is … over the last few months, it not only got above 2.50, but like 3 times it blew past 2.50 and went right to 2.70, 2.80, 2.90 and then followed by immediate BIG selling.
If people are selling just for a 30 cent profit, I wish they'd stop so we can get back above $3 at least.
Question, never heard of Cassava Sciences until your post. Looked at them.
Please give your opinion on #1, their science vs AVXL, and #2, their threat/competition vs AVXL based on both current pipelines and timelines.
Also seems to be a good question for XenaLives and others with the knowledge to share.
Thank You Again
The more long term buyers, the better for 2020.
It would certainly appear so, a lot of accumulation, on some good news, might rocket past $1 on it's way higher.
Can somebody like XenaLives or anybody who has followed this stock for a while explain why every time we get above 2.50, it goes back DOWN????
Who KEEPS selling?? Is it shorters, or insiders, or chart traders?
Somebody must have followed enough to know who consistently sells above 2.50.
This is ridiculous, great potential, nothing in stock price to show it.
at these prices - BUY NOW and then BUY MORE - big up & up in 2020.
OK, let's examine this: Every other biotech that I own is up 6% to 9% so far today. MRKR not.
We know why the others have went up today.
Just like we know why many went down at end of 2019, they went down due to tax loss selling, and also Fund managers sell their losers so those losers are not included and printed in the annual report, which makes them look bad for owning "losers".
Why up today? Those same Fund managers are snapping up what they hope will be 2020's big winners. Why is MRKR not part of this?
And it starts off today Down? Who is selling today? Not for tax loss, Not so it's not printed.
Is today sellers? OR shorters trying to continue their knocking it down and create negative sentiment to start the new year?
I mean, seriously, tell me? Who would be selling today when the markets and biotechs are doing good?
P.S. WHAT is the deal with the FDA trial Hold.
at these prices - BUY NOW and then BUY MORE - big up & up in 2020.
I heard that also. That's why I said in the past that someone like James Allison, who has huge credibility ("Hello, I won the Nobel prize") should attempt to contact these patients in need and suggest that they may want to consider MRKR MultiTAA.
Howdy and Happy New Years - Here's the story. High Hampton started as a California "Grow" operation hoping to gain large market share of what was SUPPOSED to be a HUGE money business.
Quickly realized a few problems: 1, Crazy California taxes and regulations make "Legal" weed WAY MORE expensive than illegal weed. 2, everybody and their brother started to grow and there was a huge overabundance of product with very few to sell to as most buyers were buying the much cheaper illegal weed.
Soooooooooo, they changed their path, different management, made acquisitions, changed name, going after the higher profit market products such as chocolate bars and beverages and distillates with a direct to consumer model. Has ownership of SpeedWeed to facilitate the process.
I just checked their website:
https://www.mojavejane.com/
it worked for me.
In the last couple of years it went from $1+ to it's current $0.016.
I started buying a little at $.13, a bit more at $0.09, but have been buying all I can under $0.03.
Today (Monday) out of the 18,000+ shares traded, I bought 16,400 of them. I had orders in for 50,000 at several prices but there's not a lot of volume.
I'm not worried: for every person who is selling, there is a person buying (for some reason).
Right now their market cap is 1.7 million - OK, you can buy the whole company, land, buildings, brands, network, for 1.7 million. Seems crazy cheap to me.
Pot stocks in general have bombed for the last 2 years, Tilray, Aurora, Canopy are all down 65% to 80% from highs.
People got hyped just like with bitcoin … and then it crashes … just like the tech bubble crash in March 2000.
If you want to "Buy Low and Sell High", HHPHF ain't going to get much cheaper. From over $1 per share, jumping up to 5 cents or 10 cents ain't that big of a jump for a 400% / 800% profit on any good news, and revenues should start in 2020.
If you don't buy this week, you may be very sorry by the end of February. The roll from $0.50 to $1 to $2 to $5 sometimes happens quickly in tiny biotech.
GOOD LUCK in 2020.
Alex Trebek may try experimental cancer treatment: 'I've got nothing to lose'
https://thehill.com/homenews/media/476243-alex-trebek-may-try-experimental-cancer-treatment-ive-got-nothing-to-lose
Has anyone heard anything about the FDA trial hold? We were supposed to get an answer in 30 days … like 20 days ago?
It was portrayed as Marker answers a few simple questions, which they did, and we get the trial hold taken off?
ANYWAY - MERRY CHRISTMAS - HAPPY HOLIDAYS - HAPPY NEW YEARS …
and I hope 2020 is MUCH better for MRKR holders that 2019 was.
This might be a buying opportunity …
They did an offering 2 weeks ago at .20, so they had what they thought they needed to raise then.
Then … good news at ASH.
Then … they do this offering to get the 2.5 mil compliant.
BUT, they still have the $1 minimum to be compliant.
BUT BUT, they know what they will announce what they will do with this offerings capital …. is going to raise the share price to over $1, so that solves that compliance problem.
SO, either buy it at .30 hoping it goes over $1.00.
or, buy it at .30 and watch it sit at .30.
Closed Friday at .35, buyers this pre-market at .44, then drop to .28.
Pre-market buys at .40 + .44, not a good way to start the week.
GEEZ, this may be between $1 & $2 by the end of the week.
it's Monday, the suns coming up, DO SOMETHING, GO UP THIS WEEK.
it's Monday, the suns coming up, GO UP THIS WEEK, ASH coming.
it's Monday, the suns coming up, GO UP HIGHER THIS WEEK
it's Monday, the suns coming up, GO UP THIS WEEK
AND NOW, AS USUAL, the price of AVXL will go back down, we'll be back below $2.50 soon. Just AVXL business as usual.
THEY SHOULD DO THIS IN AMERICA
Japan's Government Pension Investment Fund (GPIF), the world's largest pension fund, has suspended stock lending for short selling, calling the practice inconsistent with its responsibilities as a long-term investor.
The move, announced by the GPIF on Tuesday, is a blow for short sellers, who rely on securities lending to bet against companies and who are facing renewed moves in a number of countries to curb their activities.
"The current stock lending scheme lacks transparency in terms of who is the ultimate borrower and for what purpose they are borrowing," the GPIF said on its website.
GREAT, more patents,,, means nothing,,, as always,,, more smoke and mirrors,,, until the price goes up.
Why would a crop and food company buy ATNM?
PROOF.
As of Nov. 30th, the Canadian Stock Exchange started to publish the number of shorts on every stock.
PROOF here:
https://thecse.com/en/trading/market-activity/activity-summaries/short-positions
Link to Short Positions here:
https://www.iiroc.ca/industry/marketmonitoringanalysis/Pages/consolidated-short-position-report.aspx
Click on Nov. 21 report - Mojave Jane is listed as # 2339.
TOTAL NUMBER OF SHARES SHORT FOR "JANE" is 35,166, up 21,780 from the previous 13,386.
THAT'S IT, a TOTAL of 35,166 shares shorted.
Will Santa bring a early Christmas present in Dec. for ONTX holders?
Might be a good first two weeks of Dec.